key: cord-0701050-y0vdpngr authors: Norsa, Lorenzo; Cosimo, Paola; Indriolo, Amedeo; Sansotta, Naire; D’Antiga, Lorenzo; Callegaro, Annapaola title: Asymptomatic SARS-CoV-2 infection in patients with inflammatory bowel disease under biologic treatment date: 2020-08-26 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.08.046 sha: 8cdf28038db5e7421d76d3fa105699a034c5bc2f doc_id: 701050 cord_uid: y0vdpngr nan in the whole province, was reconverted into a COVID-19 point of care, with up to 500 beds dedicated to COVID-19 patients and over 1500 admissions for severe COVID-19 during the early phase of the local epidemic. In order to prevent SARS-CoV-2 spreading, from March 7 th the Italian government ordered the total lockdown to confine the viral diffusion. From May 4 th , when the basic reproduction number (R 0 ) dropped below 1 in the whole country, the lockdown was converted into the phase 2, that envisaged a gradual reopening of work activities, provided the maintenance of 1-meter social distancing and the use of face masks. Previous reports suggested that patients with IBD have an uneventful course during SARS-CoV-2 pandemic, including those on biologic treatment 1, 2 . Nonetheless, the rate of exposure to SARS-CoV-2 of these patients is currently unknown. This study was designed to assess the seroprevalence of COVID-19 in IBD patients undergoing biologic treatment during the main phase of the local epidemic 3 . Furthermore, we investigated the risk factors for SARS-CoV-2 infection in this cohort of subjects. This study includes all IBD patients (children and adults) undergoing biologic therapy (Infliximab, Adalimumab, Golimumab, Ustekinumab and Vedolizumab) followed at our center during the Italian COVID-19 outbreak. The time period of enrolment was divided into 2 phases: lockdown (LD)(March 4 -May 3) and Phase 2 (P2)(May 4 -July 10). During LD all patients were advised to continue their regular treatment, and were screened for SRAS-CoV-2 infection in case of suspicious clinical symptoms or contact with ascertained infected patients. From the beginning of P2 all patients were offered to perform a rapid serological test (VivaDiagTM COVID-19 IgG/IgM rapid lateral flow qualitative immunoassay, VivaChekTM Biotech, China), performed by adding 10 μl of plasma and 2 drops of dilution buffer into the sample port. After 15 minutes, the results were evaluated by the same laboratory operator who was unaware of the patient's clinical and biochemical information. The protocol was approved by the local Ethical Committee (protocol 141-20). A total of 103 patients with IBD on biologic treatment followed at our institution at the time of the study initiation completed a questionnaire exploring the presence of symptoms suggestive of SARS-CoV-2 infection as well as recent contacts with ascertained COVID-19 patients. Among them 13 (12.6%) were younger than 18 years. All SARS-CoV-2 related symptoms reported by the patients were mild, and none required hospitalization for COVID-19 (supplementary table 1) . Among them 90 patients (87%) performed the serologic test, and 19 were positive for IgG, IgM or both. This resulted in a SARS-CoV-2 seroprevalence of 21% . The comparison with a control group of health care personnel showed no significant difference in terms of global and age stratified seroprevalence (p > 0.05) (supplementary figure 1) . Remarkably, in univariate analysis, female sex, older age and presence of reported symptoms were associated with a significant increased rate of positive serology (table 1) . The multivariate analysis confirmed the protective role of male gender, while older age had a 5-fold increased risk of positive serology compared to younger age (47 years older vs 28 years younger). No positive pediatric cases were recorded. Eleven patients (58%) with a positive serology reported no symptoms during the study period. Two patients, who had persistent fever and were eventually found positive to serology testing, underwent chest computed tomography that turned up to be negative for pulmonary involvement. After more than 2 months from the first COVID-19 case of our region we found that nearly one quarter of adult patients with IBD treated with biologics has been exposed to SARS-CoV-2 infection, and that this figure is comparable to that of health care personnel working in their tertiary referral center. This suggests that the previously described uneventful course of IBD patients was not due to sheltering from the infection 1 . More than half of patients with positive SARS-CoV-2 serology were completely asymptomatic during LD, and the others reported only mild symptoms. All biologic treatments were safely administered, even at high doses for induction of remission. In this cohort, immunosuppressive treatment did not impact on SARS-CoV-2 infection outcome. Preliminary data suggest that immunosuppression is not an additional risk factor for the development of severe forms of SARS-CoV-2 infection, as it was shown also for the previous Coronaviruses pandemics SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) 4 . The only study assessing COVID-19 prevalence in IBD patients was conducted in California 5 , and reported a 3% prevalence of disease, which was comparable to the general population. This retrospective study included patients who underwent J o u r n a l P r e -p r o o f SARS-CoV-2 nasopharyngeal testing mainly because of COVID-19 related symptoms, therefore it cannot provide information on the rate of exposure to the infection of IBD patients. Preliminary data of SARS-CoV-2 serology screening carried out by the Italian government found a 24% prevalence in the general population of the Bergamo province (https://www.istat.it/it/files//2020/08/ReportPrimiRisultatiIndagineSiero.pdf), which is comparable to the prevalence we found in our IBD patients and health care personnel. The high prevalence of IBD patients having an asymptomatic course following SARS-CoV-2 infection is matter of concern when it comes to schedule hospital admissions for infusions, follow up visits or endoscopy, in regions hit by SARS-CoV-2, and suggests the need of pre-admission screening tests, in order to prevent intra-hospital dispersal of the virus. Previous findings suggesting non-adherence to biologic treatment 6 are not confirmed in our cohort, where only one patient delayed the infusion because of fear of attending the hospital during the epidemic. COVID-19 is mediated by an important cytokine storm 7 . In COVID-19 patients plasma concentrations of several cytokines, including TNF-α, were remarkably increased compared to healthy controls, especially in those with more severe disease 8 . According to those evidences and to our findings, drugs aiming at blocking TNF-α and interferon-γ signaling pathways, if not beneficial, appear not harmful during SARS-CoV-2 infection. Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing Coronaviruses and immunosuppressed patients. The facts during the third epidemic SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California Adherence of infusible biologics during the time of COVID-19 among patients with Inflammatory Bowel Disease: A nationwide VA cohort study COVID-19: consider cytokine storm syndromes and immunosuppression Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China